- Home
- BSX
as 01-17-2025 4:00pm EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 129.7B | IPO Year: | 1992 |
| Target Price: | $96.41 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.21 | EPS Growth: | 47.19 |
| 52 Week Low/High: | $59.85 - $99.14 | Next Earning Date: | 02-05-2025 |
| Revenue: | $15,911,000,000 | Revenue Growth: | 15.66% |
| Revenue Growth (this year): | 17.7% | Revenue Growth (next year): | 13.00% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brennan Daniel J. | BSX | EVP and CFO | Jan 1 '25 | Sell | $89.86 | 9,689 | $870,636.10 | 223,921 | |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Jan 1 '25 | Sell | $89.86 | 7,152 | $642,657.98 | 28,454 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Jan 1 '25 | Sell | $89.94 | 6,461 | $581,241.46 | 35,319 | |
| Carruthers Wendy | BSX | EVP, Human Resources | Dec 2 '24 | Sell | $90.78 | 6,983 | $633,916.74 | 29,308 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Nov 27 '24 | Sell | $90.65 | 1,336 | $121,105.19 | 2,957 | |
| Butcher Arthur C | BSX | EVP& Grp Pres, MedSurg & APAC | Nov 25 '24 | Sell | $89.27 | 14,010 | $1,250,664.29 | 978 | |
| LUDWIG EDWARD J | BSX | Director | Nov 21 '24 | Sell | $91.63 | 4,877 | $446,901.94 | 39,398 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Nov 8 '24 | Sell | $87.66 | 30,580 | $2,680,572.47 | 35,319 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | Nov 5 '24 | Sell | $84.96 | 162,778 | $13,794,850.92 | 1,681,387 | |
| Carruthers Wendy | BSX | EVP, Human Resources | Nov 1 '24 | Sell | $84.33 | 6,983 | $588,876.39 | 29,308 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Boston Scientific Corporation (NYSE:BSX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Zacks
3 days ago
Boston Scientific (BSX) Increases Yet Falls Behind Market: What Investors Need to Know
MT Newswires
4 days ago
Boston Scientific on Track to Be Highest Performing Medtech Firm, RBC Says
PR Newswire
5 days ago
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
Zacks
6 days ago
PBH or BSX: Which Is the Better Value Stock Right Now?
Zacks
6 days ago
M&A Synergies Drive BSX: Is it Worth Buying the Stock Now?
FX Empire
6 days ago
Boston Scientific Jumps Ahead of Earnings
MedTech Dive
6 days ago
Boston Scientific ups PFA forecast, targets market leadership
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.